NZ548086A - Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof - Google Patents

Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof

Info

Publication number
NZ548086A
NZ548086A NZ548086A NZ54808604A NZ548086A NZ 548086 A NZ548086 A NZ 548086A NZ 548086 A NZ548086 A NZ 548086A NZ 54808604 A NZ54808604 A NZ 54808604A NZ 548086 A NZ548086 A NZ 548086A
Authority
NZ
New Zealand
Prior art keywords
composition
water
sodium
counter
insulin
Prior art date
Application number
NZ548086A
Other languages
English (en)
Inventor
Chaul-Min Pai
Mi-Hong Min
Jun-Seok Hwang
Kyung-Mi Cho
Original Assignee
Samyang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Corp filed Critical Samyang Corp
Publication of NZ548086A publication Critical patent/NZ548086A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ548086A 2003-12-24 2004-12-24 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof NZ548086A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030096641A KR100638041B1 (ko) 2003-12-24 2003-12-24 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
PCT/KR2004/003448 WO2005061004A1 (en) 2003-12-24 2004-12-24 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof

Publications (1)

Publication Number Publication Date
NZ548086A true NZ548086A (en) 2008-03-28

Family

ID=36763862

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ548086A NZ548086A (en) 2003-12-24 2004-12-24 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof

Country Status (9)

Country Link
US (1) US7674767B2 (enExample)
EP (1) EP1696961A4 (enExample)
JP (1) JP4814107B2 (enExample)
KR (1) KR100638041B1 (enExample)
CN (1) CN1897975B (enExample)
AU (1) AU2004305395B2 (enExample)
CA (1) CA2549383C (enExample)
NZ (1) NZ548086A (enExample)
WO (1) WO2005061004A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2422789T (lt) 2004-05-19 2018-03-12 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injekcinės kompozicijos, apimančios natrio deoksicholiatą
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US20070021325A1 (en) * 2005-07-21 2007-01-25 Mediplex Corporation Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
KR100792557B1 (ko) * 2006-04-05 2008-01-09 한남대학교 산학협력단 나노 캡슐화를 이용하여 제조된 지질 핵 및 고분자 쉘구조를 갖는 단백질 약물 전달용 나노 미립구
WO2008067573A2 (en) * 2006-12-01 2008-06-05 Tshwane University Of Technology Drug delivery system
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
PL2200588T3 (pl) * 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
EP2243490B1 (en) * 2007-12-28 2012-06-13 Shanghai Institute of Pharmaceutical Industry Insulin nasal powder inhalation
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US9027633B2 (en) * 2008-03-24 2015-05-12 Auburn University Nanoparticle-enhanced phase change materials (NEPCM) with improved thermal energy storage
PT2345426E (pt) * 2008-09-19 2014-06-09 Activus Pharma Co Ltd Composto orgânico compósito em pó para utilização médica, método de produção do mesmo e suspensão do mesmo
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2266546A1 (en) * 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
AU2010269815B2 (en) 2009-07-09 2015-10-15 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
EP2675460A4 (en) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc TREATMENT OF FAT TISSUE UNDER CHIN
AU2012225277A1 (en) * 2011-03-10 2013-09-26 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10143754B2 (en) * 2011-08-07 2018-12-04 Transgene Biotek Limited Method for peroral delivery of insulin and its analogues for therapeutic usage
CN103957888B (zh) 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
CN102552292A (zh) * 2011-12-29 2012-07-11 石药集团欧意药业有限公司 一种阿仑膦酸钠维生素d3药物制剂
MX353567B (es) 2012-05-23 2018-01-18 Univ Ohio State Composiciones de nanoparticulas de lipidos para la entrega de oligonucleotidos antisentido.
KR101501924B1 (ko) * 2012-07-30 2015-03-18 가톨릭관동대학교산학협력단 담즙산염과 모노올레인 분산액을 포함하는 결정체, 이의 제조방법, 이를 이용한 단백질 분리 및 전달체로서의 용도
CA3209602A1 (en) 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
CN103638527A (zh) * 2013-12-05 2014-03-19 浙江大学 促红细胞生成素载药纳米粒及其应用
WO2015185180A1 (en) * 2014-06-06 2015-12-10 Merck Patent Gmbh Antigen-loaded chitosan nanoparticles for immunotherapy
WO2016004067A1 (en) * 2014-06-30 2016-01-07 Stealth Biotherapeutics Corp Aromatic-cationic peptide formulations, compositions and methods of use
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
US11246934B2 (en) * 2015-01-05 2022-02-15 B.G. Negev Technologies & Applications Ltd. At Ben-Gurion University Nanoparticles and methods for preparation thereof
US10039801B2 (en) 2016-02-16 2018-08-07 Strongbridge Ireland Limited Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use
US10213448B2 (en) 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US20180271792A1 (en) * 2017-03-23 2018-09-27 Rezolute, Inc. Oral delivery of physiologically active substances
US11660270B2 (en) 2017-07-20 2023-05-30 Indiana University Research And Technology Corporation Nanoparticle compositions
CN111902131B (zh) * 2017-11-10 2023-08-29 哈佛大学 用于降低所摄取物质的生物利用度和吸收的方法
CN112601541B (zh) * 2018-06-22 2024-12-27 比欧拉利克斯有限公司 口服给药的生物聚合物制剂
CN110720641A (zh) * 2019-10-18 2020-01-24 广东海洋大学 一种具有减脂增肌功效的蛋白冻干块及其制备方法
CN115666523A (zh) 2020-03-26 2023-01-31 Plx 奥普科有限公司 能够进行pH依赖性重构的药物载体及其制备和使用方法
US20230181471A1 (en) * 2020-07-09 2023-06-15 Hoffmann-La Roche Inc. Concentrated compositions of proteins, their preparation and use thereof
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
CN113384705A (zh) * 2021-06-28 2021-09-14 西南大学 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用
WO2023089240A1 (en) * 2021-11-19 2023-05-25 Nanoform Finland Oyj A composition comprising nanosized active pharmaceutical ingredient
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用
CN118662475A (zh) * 2023-03-16 2024-09-20 清华大学 固体化自微乳疫苗的制备与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6289617A (ja) * 1985-08-12 1987-04-24 ウイリアム　ガウフ　タツカ− 薬剤組成物およびその調製方法
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
WO1997004747A1 (en) * 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
JPH11130658A (ja) * 1997-10-30 1999-05-18 Teijin Ltd 水性懸濁医薬品組成物
JP2000024487A (ja) * 1998-07-10 2000-01-25 Nisshin Oil Mills Ltd:The 油性組成物を含有した乳化組成物
DE69921353T2 (de) * 1998-11-27 2005-11-10 Kanji Takada Oral anzuwendendes arzneimittel zur wirkstoffverabreichung im magendarmtrakt
DE19940794A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Pharmazeutische Zubereitung
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
DK1429731T3 (da) * 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
AU2002348279C1 (en) * 2001-11-13 2008-09-04 Astellas Pharma Inc. Soluble drug extended release system
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
NZ546379A (en) * 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery

Also Published As

Publication number Publication date
WO2005061004A1 (en) 2005-07-07
CN1897975B (zh) 2010-12-01
US20070154559A1 (en) 2007-07-05
CA2549383A1 (en) 2005-07-07
HK1096295A1 (en) 2007-06-01
CA2549383C (en) 2010-08-31
AU2004305395A1 (en) 2005-07-07
AU2004305395B2 (en) 2008-05-22
EP1696961A4 (en) 2010-09-01
EP1696961A1 (en) 2006-09-06
KR20050065014A (ko) 2005-06-29
JP2007517023A (ja) 2007-06-28
US7674767B2 (en) 2010-03-09
KR100638041B1 (ko) 2006-10-23
JP4814107B2 (ja) 2011-11-16
CN1897975A (zh) 2007-01-17

Similar Documents

Publication Publication Date Title
US7674767B2 (en) Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof
Alai et al. Application of polymeric nanoparticles and micelles in insulin oral delivery
AU2006221448B2 (en) Microparticle and pharmaceutical composition
JP2007517023A5 (enExample)
US9839617B2 (en) Nanoencapsulation of hydrophilic active compounds
KR20020066778A (ko) 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법
DK1742616T3 (en) The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
KR20060123384A (ko) 약물을 함유하는 나노 입자 및 그 제조 방법, 그리고 당해나노 입자로 이루어지는 비경구 투여용 제제
JP6770754B2 (ja) 輸液又は注射として及び輸液濃縮物の静脈内投与のためのレボシメンダンの改善された調製物
CN110662550A (zh) 生理活性物质的口服给药
US7087246B2 (en) Controlled release preparation of insulin and its method
JP2006199589A (ja) 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
CN116173188A (zh) 口服glp-1类似物固体脂质纳米粒及其制备方法和应用
WO2007114552A1 (en) Nanoparticles with lipid core and polymer shell structures for protein drug delivery prepared by nanoencapsulation
WO2005025542A1 (ja) 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
CN102125520A (zh) 含亲水性生物大分子的乳剂、其制备方法及用途
CN101647774A (zh) 一种细辛脑注射剂及其制备方法
US20080241260A1 (en) Compositions for Enhanced Absorption of Biologically Active Agents
HK1096295B (en) Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof
JP5098225B2 (ja) 親水性活性物質含有微粒子の製造方法

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2015 BY EARN PTY LTD

Effective date: 20140925

ERR Error or correction

Free format text: THE AGENT HAS BEEN CORRECTED TO 1434517, LTM PATENT + TRADE MARK ATTORNEYS, SUITE 4277, 24B MOOREFIELD RD, WELLINGTON 6037, NZ; THE CONTACT HAS BEEN CORRECTED TO 1434517, LTM PATENT + TRADE MARK ATTORNEYS, SUITE 4277, 24B MOOREFIELD RD, WELLINGTON 6037, NZ

Effective date: 20150720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2016 BY EARN PTY LTD

Effective date: 20151008

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2017 BY EARN PTY LTD

Effective date: 20160930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2018 BY EARN PTY LTD

Effective date: 20171002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2019 BY EARN PTY LTD

Effective date: 20181002

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2020 BY MARKPRO GLOBAL COMPANY

Effective date: 20191008

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 DEC 2021 BY MARKPRO GLOBAL COMPANY

Effective date: 20201005

LAPS Patent lapsed